Hydrogel implants with varying degrees of crosslinking
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61F-002/00
A61K-031/00
A61L-031/14
A61K-009/06
A61L-027/52
A61K-047/34
A61K-047/32
출원번호
US-0115049
(2011-05-24)
등록번호
US-8883185
(2014-11-11)
발명자
/ 주소
Bennett, Steven
Mast, Nathaniel
Lavigne, Kevin
Skalla, Walter
Banerjee, Saumya
Sargeant, Timothy
Stopek, Joshua
출원인 / 주소
Covidien LP
인용정보
피인용 횟수 :
5인용 특허 :
30
초록▼
The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying le
The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.
대표청구항▼
1. An implant comprising a hydrogel comprising: a first reactive precursor comprising a multi-arm polyether possessing electrophilic groups;a second reactive precursor comprising nucleophilic groups; andat least one initiated precursor comprising at least one vinyl group,wherein the first reactive p
1. An implant comprising a hydrogel comprising: a first reactive precursor comprising a multi-arm polyether possessing electrophilic groups;a second reactive precursor comprising nucleophilic groups; andat least one initiated precursor comprising at least one vinyl group,wherein the first reactive precursor reacts with the second reactive precursor to form a first hydrogel, and the initiated precursor forms a second hydrogel upon contact with an initiator. 2. The implant of claim 1, wherein the first reactive precursor, comprises a core selected from the group consisting of polyethylene glycol, polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block copolymers, co-polyethylene oxide random copolymers, and combinations thereof, and wherein the second reactive precursor comprises a core comprising a component selected from the group consisting of polyethylene glycol, polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block copolymers, co-polyethylene oxide random copolymers, polyvinyl alcohol, poly(vinyl pyrrolidinone), poly(amino acids), dextran, chitosan, alginates, carboxymethylcellulose, oxidized cellulose, hydroxyethylcellulose, hydroxymethylcellulose, hyaluronic acid, albumin, collagen, casein, gelatin, and combinations thereof. 3. The implant of claim 1, wherein the first reactive precursor possesses N-hydroxysuccinimide groups and the second reactive precursor possesses amine groups. 4. The implant of claim 1, wherein the initiated precursor is selected from the group consisting of acrylic acid, methacrylic acid, phosphorylcholine containing monomers, furanone functional vinyl monomers, potassium sulfopropyl acrylate, potassium sulfopropyl methacrylate, n-vinyl pyrrolidone, hydroxyethyl methacrylate, vinyl monomers having a high refractive index, siloxane functional vinyl compounds, polyethylene glycol-silicone co-monomers having vinyl groups, tris acrylate, pyrrole, liquid crystalline vinyl monomers, liquid crystalline vinyl polymers, and combinations thereof. 5. The implant of claim 1, further comprising a bioactive agent. 6. The implant of claim 1, wherein the initiator is selected from the group consisting of redox initiators, free radical initiators, radiation, and combinations thereof. 7. The implant of claim 6, wherein the radiation is selected from the group consisting of heat, visible light, ultraviolet light, gamma ray, and electron beam. 8. The implant of claim 1, wherein the second hydrogel forms a barrier layer over at least a portion of the first hydrogel. 9. The implant of claim 1, wherein the first hydrogel is placed within a tissue defect and the second hydrogel provides a barrier layer over the defect. 10. The implant of claim 1, wherein the first hydrogel has a modulus of from about 5 kPa to about 500 kPa, and the second hydrogel has a modulus of from about 50 kPa to about 5,000 kPa. 11. The implant of claim 1, wherein the first hydrogel degrades over a period of from about 4 weeks to about 10 weeks, and the second hydrogel degrades over a period of from about 6 weeks to about 6 months. 12. The implant of claim 1, wherein the implant is selected from the group consisting of matrices, artificial blood vessels, heart valves, artificial organs, bone prostheses, implantable lenticules, vascular grafts, stents, sutures, staples, clips, meshes, slings, screws, pins, cables, cartilage implants, spinal implants, and combinations thereof. 13. The implant of claim 12, wherein the implant comprises a cartilaginous implant, and wherein the first hydrogel is in a defect in cartilage and the second hydrogel forms a barrier layer over the defect. 14. The implant of claim 12, wherein the implant comprises a vertebral disc implant comprising the first hydrogel surrounded by the second hydrogel. 15. The implant of claim 12, wherein the implant comprises artificial skin. 16. A composite hydrogel composition comprising: a first hydrogel comprising a first reactive precursor comprising a multi-arm polyether possessing electrophilic groups in combination with a second reactive precursor comprising nucleophilic groups; anda second hydrogel comprising at least one initiated precursor comprising at least one vinyl group,wherein the second hydrogel forms a barrier layer over at least a portion of the surface of the first hydrogel. 17. The composite hydrogel composition of claim 16, wherein the first reactive precursor comprises a core selected from the group consisting of polyethylene glycol, polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block copolymers, co-polyethylene oxide random copolymers, and combinations thereof, and wherein the second reactive precursor comprises a core comprising a component selected from the group consisting of polyethylene glycol, polyethylene oxide, polyethylene oxide-co-polypropylene oxide, co-polyethylene oxide block copolymers, co-polyethylene oxide random copolymers, polyvinyl alcohol, poly(vinyl pyrrolidinone), poly(amino acids), dextran, chitosan, alginates, carboxymethylcellulose, oxidized cellulose, hydroxyethylcellulose, hydroxymethylcellulose, hyaluronic acid, albumin, collagen, casein, gelatin, and combinations thereof. 18. The composite hydrogel composition of claim 16, wherein the first reactive precursor possesses N-hydroxysuccinimide groups and the second reactive precursor possesses amine groups. 19. The composite hydrogel composition of claim 16, wherein the initiated precursor is selected from the group consisting of acrylic acid, methacrylic acid, phosphorylcholine containing monomers, furanone functional vinyl monomers, potassium sulfopropyl acrylate, potassium sulfopropyl methacrylate, n-vinyl pyrrolidone, hydroxyethyl methacrylate, vinyl monomers having a high refractive index, siloxane functional vinyl compounds, polyethylene glycol-silicone co-monomers having vinyl groups, tris acrylate, pyrrole, liquid crystalline vinyl monomers, liquid crystalline vinyl polymers, and combinations thereof. 20. The composite hydrogel composition of claim 16, wherein the initiated precursor reacts with an initiator selected from the group consisting of redox initiators, free radical initiators, radiation, and combinations thereof, to further crosslink the second hydrogel. 21. The composite hydrogel composition of claim 20, wherein the radiation is selected from the group consisting of heat, visible light, ultraviolet light, gamma ray, and electron beam. 22. The composite hydrogel composition of claim 16, further comprising a bioactive agent. 23. The composite hydrogel composition of claim 22, wherein the bioactive agent is in the first hydrogel. 24. The composite hydrogel composition of claim 22, wherein the bioactive agent is released from the first hydrogel over a period of time from about 3 days to about 6 weeks. 25. The composite hydrogel composition of claim 16, wherein the second hydrogel comprises from about 5% to about 30% by weight of the composite hydrogel composition. 26. The composite hydrogel composition of claim 16, further comprising a third hydrogel comprising at least one initiated precursor forming at least one disperse region within the first hydrogel. 27. The composite hydrogel composition of claim 26, wherein the second hydrogel and the third hydrogel are the same. 28. The composite hydrogel composition of claim 26, wherein the initiated precursor reacts with an initiator selected from the group consisting of redox initiators, free radical initiators, radiation, and combinations thereof, to further crosslink the third hydrogel. 29. The composite hydrogel composition of claim 28, wherein the radiation is selected from the group consisting of heat, visible light, ultraviolet light, gamma ray, and electron beam. 30. A drug delivery device comprising the composite hydrogel composition of claim 16.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (30)
Sawhney,Amarpreet S., Adhesion barriers applicable by minimally invasive surgery and methods of use thereof.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Biologically inert, biocompatible-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Collagen-polymer conjugates.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Implants coated with collagen-polymer conjugates.
Rhee Woonza M. ; Berg Richard A. ; Chu George H. ; DeLustro Frank A. ; Jolivette Dan M. ; McCullough Kimberly A., Injectable or implantable biomaterials for filling or blocking lumens and voids of the body.
Rhee Woonza (Palo Alto CA) Wallace Donald G. (Menlo Park CA) Michaels Alan S. (Boston MA) Burns ; Jr. Ramon A. (Fremont CA) Fries Louis (Los Altos CA) DeLustro Frank (Belmont CA) Bentz Hanne (Newark , Method of augmenting tissue with collagen-polymer conjugates.
Rhee Woonza M. (Palo Alto CA) Berg Richard A. (Los Altos CA) Rosenblatt Joel S. (Palo Alto CA) Tefft Jacqueline A. (Redwood City CA) Braga Larry J. (Fremont CA) Smestad Thomas L. (Palo Alto CA), Method of preparing crosslinked biomaterial compositions for use in tissue augmentation.
Hubbell Jeffrey A. (Austin TX) Pathak Chandrashekhar P. (Waltham MA) Sawhney Amarpreet S. (Newton MA) Desai Neil P. (Los Angeles CA) Hill Jennifer L. (Austin TX), Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.